Renaissance Capital logo

Harpoon Therapeutics Priced, Nasdaq: HARP

Phase 1 biotech developing T cell immunotherapies for various cancers.

Industry: Health Care

Latest Trade: $16.28 0.00 (0.0%)

First Day Return: -3.6%

Return from IPO: +16.3%

Industry: Health Care

We are a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using our proprietary TriTAC platform, we are developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Since commencing operations in 2015, we have devoted substantially all of our resources to performing research and development and manufacturing activities in support of our product development efforts, hiring personnel, raising capital to support and expand such activities and providing general and administrative support for these operations. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily from the issuance of convertible notes, the sale of convertible preferred stock and payments received under our discovery collaboration agreement with AbbVie.
more less
IPO News for Harpoon Therapeutics
more
IPO Data
IPO File Date 12/27/2018
Offer Price $14.00
Price Range $13.00 - $15.00
Offer Shares (mm) 5.4
Deal Size ($mm) $76
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/07/2019
Offer Price $14.00
Price Range $13.00 - $15.00
Offer Shares (mm) 5.4
Deal Size ($mm) $76
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters South San Francisco, CA
Founded 2015
Employees 45
Website www.harpoontx.com